Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Tao, Chang Juan ^a,b   Lin, Li ^a   Zhou, Guan Qun ^a   Tang, Ling Long ^a   Chen, Lei ^a   Mao, Yan Ping ^a   Zeng, Mu Sheng ^a   Kang, Tie Bang ^a   Jia, Wei Hua ^a   Shao, Jian Yong ^a   Mai, Hai Qiang ^a   Lin, Ai Hua ^c   Ma, Jun ^a   Sun, Ying ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DERMATITIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; RADIATION DOSE DISTRIBUTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; XEROSTOMIA; ADOLESCENT; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; RADIATION DOSE;

ADOLESCENT; ADULT; AGED; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84908027223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110765     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2009) American Joint Committee on Cancer Manual for Staging of Cancer [M]. 7th ed. Philadelphia: JB Lippincott. 649 p.
3. Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, et al. (2012) The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiat Oncol Biol Phys 104: 331-337.
4. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, et al. (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 16: 1310-1317.
5. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, et al. (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23: 6966-6975.
6. Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, et al. (2010) Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs. radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 102: 1188-1198.
7. Chen Y, Sun Y, Liang SB, Zong JF, Li WF, et al. (2013) Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 119: 2230-2238.
8. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, et al. (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97: 536-539.
9. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, et al. (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21: 631-637.
10. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, et al. (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13: 163-171.
11. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, et al. (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64: 47-56.
12. Jagdis A, Laskin J, Hao D, Hay J, Wu J, et al. (2012) Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC). Am J Clin Oncol Oct 29.
13. Peng G, Wang T, Yang KY, Zhang S, Zhang T, et al. (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104: 286-293.
14. Zhao C, Han F, Lu LX, Huang SM, Lin CG, et al. (2004) Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma. Ai Zheng 23: 1532-1537.
15. Liang S, Sun Y, Liu L, Chen Y, Chen L, et al. (2009) Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys 75: 742-750.
16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481.
17. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-220.
18. Lee AWM, Ng WT, Chan OSH, Sze HCK (2012) If concurrent-adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction-concurrent achieve better outcome? J Radiat Oncol 1: 107-115.
19. OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, et al. (2013) Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 24: 2136-2146.
20. Ho KF, Swindell R, Brammer CV (2008) Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 47: 1513-1518.
21. Loong HH, Ma BB, Leung SF, Mo F, Hui EP, et al. (2012) Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 104: 300-304.
22. Chen QY, Wen YF, Guo L, Liu H, Huang PY, et al. (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103: 1761-1770.